https://pristineorganics.com/metabollic-diets-for-iem-inborn-errors-of-metabollism/
https://brawnraredisease.in/
They with Vitaflo International Ltd and has the rights to distribute its FSMP products to patients with Tyrosinemia Type-1 and Phenylketonuria in India who suffer from rare IEM diseases.
Diet Help
If any Parent/Doctor want Life saving diet
Kindly contact Ms Sarika Modi
Email; sarika.iemsp@gmail.com , sarika@spreadhome.com
Mobile number : 9810746265
Contact 4pm tp 6pm
Diet Help
https://www.abbottnutrition.com/metabolic-nutrition
https://hcp.meadjohnson.com/s/products/category/a4K4J000001uk2MUAQ/metabolic
https://www.nutricia.com/specialize/iem.html
https://www.nestlehealthscience.co.uk/vitaflo/home-delivery/home
https://fssai.gov.in/upload/knowledge_hub/1385075b34be3d5828aDiet4Life.pdf
FSSAI Diet For Life
https://eatrightindia.gov.in/diet4life/
https://fssai.gov.in/cms/diet4life.php
https://www.fodsupport.org/medical-info
Medicines for IEMS in India
https://www.isiem.org/wp-content/uploads/2024/08/6.-Medical-Supplements-for-IEMs.pdf
Brawn Laboratories Ltd
Nitisinone Tablets (2mg/5mg/10mg) for the treatment of Tyrosinemia Type-1
Eliglustat 84mg Caps for the treatment of Gaucher's disease.
LARGLUSTAT is now available in the market.
Sodium Phenylbutyrate
AMMOBULA (Sodium phenylbutyrate oral powder 100gm) for the treatment of Urea Cycle Disorder (UCD).
Akums Drugs and Pharma secures patent for new drug to manage sickle cell disease
Akums Drugs and Pharmaceuticals has secured a patent for a room-temperature stable Oral Suspension of Hydroxyurea, helping with Sickle Cell Disease management without the need for refrigeration.
https://www.indiatoday.in/health/story/akums-drugs-and-pharma-secures-patent-for-new-sickle-cell-disease-treatment-hydroxyurea-2599310-2024-09-13?utm_source=chatgpt.com
In India, Sanofi (formerly Genzyme) and Takeda are the primary pharmaceutical companies providing Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders (LSDs).While other global companies like AstraZeneca and Roche operate in the rare disease space in India, their focus is currently on other types of treatments (such as oral therapies or biologics for SMA and Rare Blood Disorders) rather than traditional ERT.
Primary Providers of ERT in India Company
Key ERT Products Rare Diseases Covered
Sanofi (Sanofi Genzyme) Cerezyme, Fabrazyme, Myozyme, Aldurazyme, Nexviazyme
Gaucher, Fabry, Pompe, MPS I, ASMD
Takeda Pharmaceuticals
Vpriv, Elaprase, Replagal
Gaucher, Hunter Syndrome (MPS II), Fabry
The Central Government has given full exemption from basic customs duty on all drugs and Food for Special Medical Purposes imported for personal use for treatment of all Rare Diseases listed under the National Policy for Rare Diseases 2021 through a general exemption notification.
https://www.pib.gov.in/PressReleasePage.aspx?PRID=1912095
The information provided has been sourced from various websites and articles.By no means we claim to be exhaustive or up-to-date.